Loading
Geriatric assessment is a structured check of an older patient's fitness, memory, and support that predicts treatment tolerance better than age.
Geriatric assessment scores validated domains, including function, comorbidity, cognition, nutrition, and social support, to predict how an older patient will tolerate treatment and to guide dose and regimen choice, which age alone does poorly. The GAP70+ and GAIN trials showed that geriatric-assessment-guided management reduces severe chemotherapy toxicity by roughly 20% without compromising survival. ASCO recommends it for all patients aged 65 or over receiving chemotherapy. It reduces harm and improves shared decision-making, giving patients a clearer picture of what treatment will cost them. Time and uptake are the barriers, since the assessment adds clinic work that many services have not resourced. The simple version is a structured fitness check that tells the oncologist how much treatment an older person can safely take.
Validated domains (function, comorbidity, cognition, nutrition, social support) inform dose and regimen choice.
Query for this technology: (TITLE:"geriatric assessment" OR ABSTRACT:"geriatric assessment") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Geriatric assessment, not a curated reading list.
Shares Virginia Sun, Catch wasting early with a smart scale and a step counter, Qualify a physical function endpoint so anti-wasting drugs can be approved, Treat wasting like sepsis: a trigger, a bundle, an audit.
Shares Surgical morbidity and postoperative complications, Prehabilitation (the pre-treatment window), A dietitian in every gastrointestinal and head and neck tumour board, What a prehabilitation programme actually contains, and how long it needs.
Shares Cachexia-directed therapy (GDF-15 blockade), A dietitian in every gastrointestinal and head and neck tumour board, Cancer cachexia, Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA).
Shares Prehabilitation (the pre-treatment window), Four weeks of training and nutrition before major cancer surgery, as standard, What a prehabilitation programme actually contains, and how long it needs, Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA).
Shares Wearables and step counts: measuring what someone actually does, What a prehabilitation programme actually contains, and how long it needs, Muscle and strength after treatment: sarcopenia, cachexia and what rebuilds, What the randomised trials of prehabilitation found, operation by operation.
Shares Qualify a physical function endpoint so anti-wasting drugs can be approved, Cachexia-directed therapy (GDF-15 blockade), Cancer cachexia, CT body composition and sarcopenia measurement.
Shares Catch wasting early with a smart scale and a step counter, Treat wasting like sepsis: a trigger, a bundle, an audit, Read muscle loss automatically from scans patients already have, Four weeks of training and nutrition before major cancer surgery, as standard.
Shares Gary H. Lyman, A dedicated programme for cachexia and treatment toxicity research, Multinational Association of Supportive Care in Cancer, Paths to cures: interception, eradication, control.